{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T18:54:25Z","timestamp":1725562465590},"reference-count":0,"publisher":"Biomedical Informatics","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bioinformation"],"published-print":{"date-parts":[[2022,2,28]]},"abstract":"<jats:p>Myo-Inositol and D-chiro-inositol (MI-DCI) are used in the treatment of polycystic ovarian syndrome (PCOS) due to their insulin-sensitizing actions. Therefore, it is of interest to evaluate the treatment patterns, clinical effectiveness and safety of MI-DCI combination in management of PCOS in Indian women .Data from 50 healthcare centers across India between September 2019 and February 2020 were used in the study. Women aged 12-45 years diagnosed with PCOS, who had received MI-DCI (550-150 mg) were included. The outcome parameters were change in weight, luteinizing hormone (LH)\/follicle stimulating hormone (FSH) ratio, hirsutism, blood glucose and insulin levels, HOMA-IR, and lipid profile. 283 women (mean age: 27.74 years; body mass index: 26.89 kg\/m2); of which 197 (69.61%) reported reduction in weight after treatment with MI-DCI. The proportion of hirsutism score reduced after treatment, no hirsutism increased from 31.07% to 50.51% and the severe reduced from 4.85% to zero and moderate from 32.52% to 6.12%. There was a significant reduction in LH:FSH ratio (mean difference: 0.25 mg\/dL; p=0.021), free testosterone (mean difference: 1.49; p&lt;0.001) and dehydroepiandrosterone (mean difference: 21.49; P&lt;0.001) levels after regular use of MI-DCI tablets.Treatment with MI-DCI resulted in significant improvement in insulin, HOMA score, FPG, PPG and lipid profile. The therapy restored menstruation and spontaneous ovulation and significantly attenuated the LH\/FSH ratio. Thus, MI-DCI (550-150 mg) has shown multidimensional benefits in improving the hormonal, glycemic, and lipid profile of women with PCOS with considerable efficacy and tolerability.<\/jats:p>","DOI":"10.6026\/97320630018103","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:03:08Z","timestamp":1644472988000},"page":"103-110","source":"Crossref","is-referenced-by-count":2,"title":["Management of polycystic ovary syndrome among Indian women using myo\u2010inositol and D-chiro-inositol"],"prefix":"10.6026","volume":"18","author":[{"name":"Vyas clinic, Jaipur, India","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lila","family":"Vyas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4070","published-online":{"date-parts":[[2022,2,28]]},"container-title":["Bioinformation"],"original-title":[],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:03:11Z","timestamp":1644472991000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.bioinformation.net\/018\/97320630018103.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,28]]},"published-print":{"date-parts":[[2022,2,28]]}},"URL":"https:\/\/doi.org\/10.6026\/97320630018103","relation":{},"ISSN":["0973-8894","0973-2063"],"issn-type":[{"type":"print","value":"0973-8894"},{"type":"electronic","value":"0973-2063"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}